|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IFI27L1 |
Gene summary for IFI27L1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IFI27L1 | Gene ID | 122509 |
| Gene name | interferon alpha inducible protein 27 like 1 | |
| Gene Alias | FAM14B | |
| Cytomap | 14q32.12 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | Q96BM0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 122509 | IFI27L1 | LZE7T | Human | Esophagus | ESCC | 8.97e-08 | 2.62e-01 | 0.0667 |
| 122509 | IFI27L1 | LZE20T | Human | Esophagus | ESCC | 3.07e-03 | 1.34e-01 | 0.0662 |
| 122509 | IFI27L1 | LZE24T | Human | Esophagus | ESCC | 1.60e-11 | 3.58e-01 | 0.0596 |
| 122509 | IFI27L1 | LZE6T | Human | Esophagus | ESCC | 1.63e-02 | 1.14e-01 | 0.0845 |
| 122509 | IFI27L1 | P1T-E | Human | Esophagus | ESCC | 3.86e-03 | 1.94e-01 | 0.0875 |
| 122509 | IFI27L1 | P2T-E | Human | Esophagus | ESCC | 3.86e-20 | 2.25e-01 | 0.1177 |
| 122509 | IFI27L1 | P4T-E | Human | Esophagus | ESCC | 3.78e-16 | 4.12e-01 | 0.1323 |
| 122509 | IFI27L1 | P5T-E | Human | Esophagus | ESCC | 7.39e-14 | 2.72e-01 | 0.1327 |
| 122509 | IFI27L1 | P8T-E | Human | Esophagus | ESCC | 7.01e-19 | 1.10e-01 | 0.0889 |
| 122509 | IFI27L1 | P9T-E | Human | Esophagus | ESCC | 3.97e-09 | 1.95e-01 | 0.1131 |
| 122509 | IFI27L1 | P10T-E | Human | Esophagus | ESCC | 9.75e-18 | 2.73e-01 | 0.116 |
| 122509 | IFI27L1 | P11T-E | Human | Esophagus | ESCC | 1.07e-11 | 6.10e-01 | 0.1426 |
| 122509 | IFI27L1 | P12T-E | Human | Esophagus | ESCC | 5.37e-24 | 5.03e-01 | 0.1122 |
| 122509 | IFI27L1 | P15T-E | Human | Esophagus | ESCC | 3.41e-33 | 5.96e-01 | 0.1149 |
| 122509 | IFI27L1 | P16T-E | Human | Esophagus | ESCC | 4.31e-13 | 1.27e-01 | 0.1153 |
| 122509 | IFI27L1 | P17T-E | Human | Esophagus | ESCC | 1.12e-10 | 4.84e-01 | 0.1278 |
| 122509 | IFI27L1 | P20T-E | Human | Esophagus | ESCC | 2.21e-19 | 3.51e-01 | 0.1124 |
| 122509 | IFI27L1 | P21T-E | Human | Esophagus | ESCC | 3.06e-30 | 5.53e-01 | 0.1617 |
| 122509 | IFI27L1 | P22T-E | Human | Esophagus | ESCC | 1.48e-21 | 3.41e-01 | 0.1236 |
| 122509 | IFI27L1 | P23T-E | Human | Esophagus | ESCC | 5.04e-13 | 2.45e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IFI27L1 | SNV | Missense_Mutation | novel | c.268N>A | p.Ala90Thr | p.A90T | Q96BM0 | protein_coding | tolerated(0.32) | benign(0.039) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IFI27L1 | SNV | Missense_Mutation | novel | c.299C>T | p.Ser100Leu | p.S100L | Q96BM0 | protein_coding | deleterious(0.01) | benign(0) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| IFI27L1 | SNV | Missense_Mutation | novel | c.274N>C | p.Thr92Pro | p.T92P | Q96BM0 | protein_coding | tolerated(0.09) | benign(0.335) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IFI27L1 | SNV | Missense_Mutation | novel | c.155N>A | p.Ser52Tyr | p.S52Y | Q96BM0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IFI27L1 | SNV | Missense_Mutation | rs200682471 | c.55N>A | p.Gly19Arg | p.G19R | Q96BM0 | protein_coding | deleterious(0.01) | benign(0.289) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IFI27L1 | deletion | Frame_Shift_Del | novel | c.301delN | p.Pro102LeufsTer18 | p.P102Lfs*18 | Q96BM0 | protein_coding | TCGA-D1-A177-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| IFI27L1 | SNV | Missense_Mutation | novel | c.175N>T | p.Gly59Trp | p.G59W | Q96BM0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-55-A4DG-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| IFI27L1 | SNV | Missense_Mutation | novel | c.147N>T | p.Lys49Asn | p.K49N | Q96BM0 | protein_coding | deleterious(0.04) | possibly_damaging(0.537) | TCGA-CV-5432-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| IFI27L1 | SNV | Missense_Mutation | novel | c.59N>C | p.Gly20Ala | p.G20A | Q96BM0 | protein_coding | tolerated(0.18) | benign(0.152) | TCGA-CV-6936-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |